LitCovid-sample-Enju  

PMC:7205724 / 1441-1769 JSONTXT 16 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T219 2-10 NNS denotes patients
T220 11-15 IN denotes with
T221 16-24 NN denotes COVID-19
T222 26-37 NNP denotes Tocilizumab
T223 37-38 -COMMA- denotes ,
T224 39-40 DT denotes a
T225 41-51 JJ denotes monoclonal
T226 52-60 NN denotes antibody
T227 61-68 IN denotes against
T228 69-72 NN denotes IL6
T229 72-73 -COMMA- denotes ,
T230 74-79 MD denotes could
T231 80-86 VB denotes confer
T232 87-95 JJ denotes clinical
T233 96-103 NN denotes benefit
T234 104-106 IN denotes in
T235 107-115 NNS denotes patients
T236 116-120 IN denotes with
T237 121-125 JJ denotes high
T238 126-129 NN denotes IL6
T239 130-136 NNS denotes levels
T240 138-147 JJ denotes Essential
T241 148-156 NNS denotes elements
T242 157-161 IN denotes that
T243 162-169 NN denotes process
T244 170-179 NN denotes SARS-CoV2
T245 180-184 NN denotes cell
T246 185-190 NN denotes entry
T247 191-194 CC denotes and
T248 195-203 JJ denotes specific
T249 204-219 NNS denotes characteristics
T250 220-224 WDT denotes that
T251 225-230 VBP denotes allow
T252 231-240 NN denotes SARS-CoV2
T253 241-243 TO denotes to
T254 244-250 VB denotes escape
T255 251-254 DT denotes the
T256 255-261 JJ denotes immune
T257 262-268 NN denotes system
T258 269-273 VBP denotes have
T259 274-277 DT denotes the
T260 278-287 NN denotes potential
T261 288-290 IN denotes as
T262 291-298 NNS denotes targets
T263 299-302 IN denotes for
T264 303-311 NN denotes COVID-19
T265 312-319 NN denotes therapy
T266 322-323 CD denotes 1
R211 T219 T220 arg1Of patients,with
R212 T221 T220 arg2Of COVID-19,with
R213 T222 T223 arg1Of Tocilizumab,","
R214 T226 T223 arg2Of antibody,","
R215 T226 T224 arg1Of antibody,a
R216 T226 T225 arg1Of antibody,monoclonal
R217 T226 T227 arg1Of antibody,against
R218 T228 T227 arg2Of IL6,against
R219 T231 T229 arg1Of confer,","
R220 T222 T230 arg1Of Tocilizumab,could
R221 T231 T230 arg2Of confer,could
R222 T222 T231 arg1Of Tocilizumab,confer
R223 T233 T231 arg2Of benefit,confer
R224 T233 T232 arg1Of benefit,clinical
R225 T231 T234 arg1Of confer,in
R226 T235 T234 arg2Of patients,in
R227 T235 T236 arg1Of patients,with
R228 T239 T236 arg2Of levels,with
R229 T239 T237 arg1Of levels,high
R230 T239 T238 arg1Of levels,IL6
R231 T241 T240 arg1Of elements,Essential
R232 T241 T242 arg1Of elements,that
R233 T247 T242 arg2Of and,that
R234 T258 T242 arg3Of have,that
R235 T246 T243 arg1Of entry,process
R236 T246 T244 arg1Of entry,SARS-CoV2
R237 T246 T245 arg1Of entry,cell
R238 T246 T247 arg1Of entry,and
R239 T249 T247 arg2Of characteristics,and
R240 T249 T248 arg1Of characteristics,specific
R241 T249 T250 arg1Of characteristics,that
R242 T249 T251 arg1Of characteristics,allow
R243 T252 T251 arg2Of SARS-CoV2,allow
R244 T254 T251 arg3Of escape,allow
R245 T254 T253 arg1Of escape,to
R246 T252 T254 arg1Of SARS-CoV2,escape
R247 T257 T254 arg2Of system,escape
R248 T257 T255 arg1Of system,the
R249 T257 T256 arg1Of system,immune
R250 T247 T258 arg1Of and,have
R251 T260 T258 arg2Of potential,have
R252 T260 T259 arg1Of potential,the
R253 T258 T261 arg1Of have,as
R254 T262 T261 arg2Of targets,as
R255 T262 T263 arg1Of targets,for
R256 T265 T263 arg2Of therapy,for
R257 T265 T264 arg1Of therapy,COVID-19